Navigation Links
Preclinical Research on Coronary Stent with CeloNova BioSciences' Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
Date:9/8/2007

ATLANTA, Sept. 9 /PRNewswire/ -- Celonova Biosciences, Inc. ("CeloNova"), a leading developer of innovative medical devices, today announced that the paper, "Comparison of late in-stent stenosis and vessel wall inflammation in Cypher(R) Select(TM), Taxus(R) Express(TM), and Polyzene(R)-F nanocoated cobalt chromium stents in a porcine coronary artery model" prepared by Dr. Boris Radeleff has been chosen to receive the CIRSE 2007 Magna Cum Laude EPOS Award.

"We are delighted that Dr. Radeleff has been honored by his peers for his work comparing the performance of the leading drug-eluting stents to a stent treated with CeloNova's proprietary Polyzene(R)-F medically inert surface coating," said Thomas A. Gordy, CeloNova President and Chief Executive Officer. "This award validates the high quality of the work undertaken by Dr. Radeleff and his colleagues to understand how Polyzene(R)-F can enhance the performance of coronary stents by inhibiting restenosis and thrombus formation without the need to resort to an anti-proliferative drug or long-term dual antiplatelet medications. We continue to believe, based on this and other ongoing research, that Polyzene(R)-F represents a revolutionary breakthrough in the quest to develop the ideal long-term solution for coronary stenting."

Dr. Radeleff, a physician at the University Hospital of Heidelberg, received his award at the CIRSE Opening Ceremony and Awards Session in Athens, Greece on Saturday, September 08.

About CIRSE

The Cardiovascular and Interventional Radiological Society of Europe is a non-profit making, educational and scientific association of 2,300 interventional professionals with an active personal involvement and interest in interventional radiology or cardiovascular imaging techniques.

About CIRSE 2007

The CIRSE Annual Scientific and Postgraduate Educational Meeting has established itself as the premier gathering for all professionals devoted to the field of Cardiovascular and Interventional Radiology in Europe. CIRSE 2007 is a unique forum where medical professionals can meet their colleagues from all around the world, and exchange ideas and information in the field of minimally invasive, image guided therapies.

About CeloNova BioSciences, Inc.

Headquartered near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, and possesses both anti-bacterial and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes its Embozene(TM) Microspheres, used to treat arteriovenous malformations, hypervascularized tumors, uterine fibroids and hepatocellular carcinoma. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Contact: Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
3. Control Your siRNA Research
4. Getting Started with MicroRNA Research
5. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
6. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
7. Research Organics
8. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
9. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
10. Research Tools for Analysis of ZAP-70
11. Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, ... latest paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 ... Dr. Bik joined uBiome in October 2016 from her previous position at Stanford ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017  HUYA Bioscience ... of China,s pharmaceutical innovations, announced ... of Sciences Innovation and Investment Company (referred to as ... commercializing biomedical innovations discovered by leading scientists at CAS ... world. HUYA is the first company to ...
Breaking Biology Technology:
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
(Date:12/8/2016)... -- Singulex, Inc., the leader in Next Generation Immunodiagnostics powered ... and supply agreement with Thermo Fisher Scientific, the world ... to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker which, ... diagnose systemic bacterial infection and sepsis and in ... assessing the risk of critically ill patients for progression ...
Breaking Biology News(10 mins):